ImmuneWorks

About:

ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung.

Top Investors: BioCrossroads

Description:

ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung. The company was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients. It was incorporated in 2006 and is based in Indianapolis, Indiana.

Total Funding Amount:

$735000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Indianapolis, Indiana, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)immuneworks.com

Founders:

David Wilkes, Ronald Meeusen

Number of Employees:

1-10

Last Funding Date:

2013-12-26

IPO Status:

Private

Industries: